Gothenberg -based biotech company Verigraft A € 1.2 million euroster grant has been provided to lead the appropriate printed personalized tissue therapy (preper) project to develop the next generation’s 3D-printed arteries.
This initiative tries to solve significant challenges in current graft technology, including limited availability of human-donated materials, weak integration and high failure rates. The success of the project can facilitate the initial human clinical trial and future commercialization, potential applications extend out of vascular graft.
“This Eurosters grant is a major milestone for Verigraft and regenerative drugs. Including the preper, we are accelerating the future of personalized tissue therapy“Said Dr. Raimund StrahlCTO of Verigraft. “The Global Vaskular Graft Market will be more than $ 1 billion by 2026 and prep’s position on Europe’s position at the top of 3D bioprinting and regenerative drugsThe “
Established by Jan Hololson in the 21st, a biotechnology company, which is mainly mainly at the Verigert Karolinska Institute, has become the pioneer of industrialized tissue engineering and advanced regenerative medicine.
Personalized tissues have a centralized research and de pipeline targeting regions such as cardiovascular and neuronal disease. Verigraft will commercially commercially commercially a series of personalized tissue-engineers graft in the global market.
“Verigert provides a unique, epoch -making technology for advanced regenerative drugs. The technology gives the tissue and organs the opportunity to personalize. It will be able to bring an instance of shift to replacement drugs“Said Peter Bizarcist PhD, Chief Executive Officer.
In an ongoing trial, Verigert has successfully replaced their personalized tissue-engineied vein, P-TV ™, a condition that affects the deep vein system that affects low-lying abscesses and ulceration that influences low-lying vein (CVI). The legs take painful swelling and ulceration. Significantly, a Spanish patient can now walk for the first time for the first time year after year and participate in a football match.
Easily cooperates with 3DSA (Switzerland), Rise (Sweden), and Sahlginska University Hospital (Sweden), will integrate Verigraft advanced 3D printing, solution-blown fiber technology and personalized tissue engineering. The goal is to create a customized vascular graft that duplicates the natural arteries, provides higher durability and non -existing integration than current synthetic options.
The Prepara project has received the European Union’s Horizon Europe Research and Innovation Program, with the Europers -3 joint program. Eurosters are part of the European partnership in innovative SMEs.
Through the benefits of these grants and allied skills, the aim of Verigert was to revolutionize the regenerative drugs, provide innovative solutions to patients needed for arterial graphs, and to position Europe as a top in 3D bioprinting technology.
[publish_date
